MAX Chat
Company Analysis Taro Pharmaceutical Industries Ltd.
1. Summary
Advantages
- The stock's return over the last year (0%) is higher than the sector average (-48.5%).
- The company's current efficiency (ROE=3.06%) is higher than the sector average (ROE=-70.06%)
Disadvantages
- Price (42.3 $) is higher than fair price (12.29 $)
- Dividends (0%) are below the sector average (1.29%).
- Current debt level 0.0902% has increased over 5 years from 0%.
Similar companies
2. Share price and performance
2.1. Share price
2.3. Market efficiency
| Taro Pharmaceutical Industries Ltd. | Healthcare | Index | |
|---|---|---|---|
| 7 days | 0% | -5.9% | 2% |
| 90 days | 0% | -42.2% | 9.8% |
| 1 year | 0% | -48.5% | 17.3% |
TARO vs Sector: Taro Pharmaceutical Industries Ltd. has outperformed the "Healthcare" sector by 48.5% over the past year.
TARO vs Market: Taro Pharmaceutical Industries Ltd. has significantly underperformed the market by -17.31% over the past year.
Stable price: TARO is not significantly more volatile than the rest of the market on "New York Stock Exchange" over the last 3 months, with typical variations of +/- 5% per week.
Long period: TARO with weekly volatility of 0% over the past year.
3. Summary of the report
4. Fundamental Analysis
4.1. Stock price and price forecast
Above fair price: The current price (42.3 $) is higher than the fair price (12.29 $).
Price is higher than fair: The current price (42.3 $) is 70.9% higher than the fair price.
4.2. P/E
P/E vs Sector: The company's P/E (29.47) is higher than that of the sector as a whole (27.78).
P/E vs Market: The company's P/E (29.47) is lower than that of the market as a whole (50.97).
4.2.1 P/E Similar companies
4.3. P/BV
P/BV vs Sector: The company's P/BV (0.8854) is lower than that of the sector as a whole (10.53).
P/BV vs Market: The company's P/BV (0.8854) is lower than that of the market as a whole (18.11).
4.3.1 P/BV Similar companies
4.4. P/S
P/S vs Sector: The company's P/S indicator (2.52) is lower than that of the sector as a whole (4.07).
P/S vs Market: The company's P/S indicator (2.52) is lower than that of the market as a whole (27.96).
4.4.1 P/S Similar companies
4.5. EV/Ebitda
EV/Ebitda vs Sector: The company's EV/Ebitda (23.28) is higher than that of the sector as a whole (18.1).
EV/Ebitda vs Market: The company's EV/Ebitda (23.28) is lower than that of the market as a whole (39.19).
5. Profitability
5.1. Profitability and revenue
5.2. Earnings per share - EPS
5.3. Past profitability Net Income
Yield Trend: Negative and has fallen by -15.58% over the last 5 years.
Accelerating profitability: The return for the last year (0%) exceeds the average return for 5 years (-15.58%).
Profitability vs Sector: The return for the last year (0%) is lower than the return for the sector (1364.64%).
5.4. ROE
ROE vs Sector: The company's ROE (3.06%) is higher than that of the sector as a whole (-70.06%).
ROE vs Market: The company's ROE (3.06%) is lower than that of the market as a whole (34.58%).
5.5. ROA
ROA vs Sector: The company's ROA (2.51%) is lower than that of the sector as a whole (8.48%).
ROA vs Market: The company's ROA (2.51%) is lower than that of the market as a whole (11.54%).
5.6. ROIC
ROIC vs Sector: The company's ROIC (-0.34%) is lower than that of the sector as a whole (21.56%).
ROIC vs Market: The company's ROIC (-0.34%) is lower than that of the market as a whole (10.02%).
7. Dividends
7.1. Dividend yield vs Market
Low yield: The dividend yield of the company 0% is below the average for the sector '1.29%.
7.2. Stability and increase in payments
Unstable dividends: The company's dividend yield 0% has not been consistently paid over the past 7 years, DSI=0.5.
Weak dividend growth: The company's dividend yield 0% has been growing weakly or stagnant over the past 5 years. Growth over only 1 year.
7.3. Payout percentage
Dividend Coverage: Current payments from income (0%) are at an uncomfortable level.
Pay for your subscription
More functionality and data for company and portfolio analysis is available by subscription
